Biogen

Views & Analysis

Bridging the gap between pharma and the NHS in MS

Janette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis (MS) field teams and developing patient and Healthcare Professiona

News

FDA panel unimpressed with data for Alzheimer’s drug aducanu...

The FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors have little doubt that the evidence for the drug is lacking.<

News

Closeup of X-ray photography of human brain

China's Green Valley prepares US trial of Alzheimer's drug i...

As an influential panel of FDA-appointed experts prepares its verdict on Biogen’s Alzheimer’s drug, a little known China-based pharma is hoping to succeed where big name rivals have failed

News

Trials and tribulations in Biogen's Alzheimer’s drug reviews

Regulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate is still ongoing about whether the data behind the drug is strong enough

News